Evgen Pharma

finnCap has advised Evgen Pharma on a heavily oversubscribed Placing & Open Offer to raise up to £11m. Proceeds are intended to:

– Fund further preclinical work for metastatic breast cancer (mBC) glioma & further cancer indication
– Subject to further pre-clinical progress fund a clinical trial in glioma patients
– Complete formulation & scale up manufacture of SFX-01
– Complete all preparatory work required to file IND application for SFX-01
– Fund operations through to mid-2023 incl. key senior hiresEVGEN PHARMA PLC

Huw Jones, CEO, Evgen Pharma: “The board are delighted to have raised this transformational sum and we are thankful to all our advisers who helped us through the process. finnCap provided us with sensible, commercial advice and were key in accessing the significant capital we have secured through this funding. We are pleased to welcome a number of new high quality shareholders to our register and were most grateful for the support shown in this placing by existing shareholders. This heavily oversubscribed fundraising allows us to accelerate both our future clinical and current pre-clinical work dramatically, together with expanding our senior management team to support our growth. We look forward to accelerating our progress in a range of cancers and acute respiratory distress.”